Genovate Biotechnology Co., Ltd. Reports Earnings Results for the Second Quarter Ended June 30, 2021
August 13, 2021 at 05:33 pm EDT
Share
Genovate Biotechnology Co., Ltd. announced earnings results for the second quarter ended June 30, 2021. For the second quarter, the company announced sales was TWD 100.283 million compared to TWD 124.033 million a year ago. Operating loss was TWD 3.375 million compared to operating Income of TWD 15.166 million a year ago. Net loss was TWD 2.908 million compared to net income of TWD 14.089 million a year ago. Basic loss per share was TWD 0.03 compared to basic earnings per share of TWD 0.13 a year ago. For the half year, sales was TWD 203.833 million compared to TWD 259.868 million a year ago. Operating income was TWD 3.307 million compared to TWD 34.468 million a year ago. Net income was TWD 5.745 million compared to TWD 32.668 million a year ago. Basic earnings per share was TWD 0.05 compared to TWD 0.31 a year ago.
Genovate Biotechnology Co., LTD. is a Taiwan-based company principally engaged in the research, development, manufacture and sales of pharmaceutical preparations, drug substances and intermediates. The Company's products include nervous system drugs, digestive system drugs, analgesic and anti-inflammatory drugs, urogenital system drugs, antimicrobial drugs, cardiovascular system drugs, acne drugs, antineoplastic drugs and anti-diabetic drugs, as well as healthcare food and cosmetics. The Company is also engaged in the provision of clinical experimental testing services and technology export services. The Company distributes its products mainly within domestic market.
GENOVATE BIOTECHNOLOGY CO., LTD. 